Anzeige
Meldung des Tages: Lettland-Defence-Zertifikat! Diese Aktie öffnet die Tür zu bis zu 3 Mio. € Finanzierung

Ideaya Bioscience Aktie News

Aktie
WKN:  A2PJPB ISIN:  US45166A1025 US-Symbol:  IDYA Branche:  Biotechnologie Land:  USA
27,10 €
+0,00 €
0,00%
12:19:06 Uhr
Depot/Watchlist
Marktkapitalisierung *
2,62 Mrd. €
Streubesitz
-
KGV
-28,46
Nachhaltigkeits-Score
22 %
Index-Zuordnung
-

Ideaya Bioscience News

17.02.26 - PR Newswire
IDEAYA Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update
IDEAYA Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update PR Newswire
02.02.26 - PR Newswire
IDEAYA Biosciences to Participate in Upcoming February 2026 Investor Relations Events
IDEAYA Biosciences to Participate in Upcoming February 2026 Investor Relations Events PR Newswire
30.01.26 - PR Newswire
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) PR Newswire
11.01.26 - PR Newswire
IDEAYA Biosciences Provides a Business Update and Outlines 2026 Corporate Objectives at the 44th Annual J.P. Morgan Healthcare Conference
IDEAYA Biosciences Provides a Business Update and Outlines 2026 Corporate Objectives at the 44th Annual J.P. Morgan Healthcare Conference PR Newswire
05.01.26 - PR Newswire
IDEAYA Biosciences Announces Participation at the 44th Annual J.P. Morgan Healthcare Conference
IDEAYA Biosciences Announces Participation at the 44th Annual J.P. Morgan Healthcare Conference PR Newswire
11.12.25 - PR Newswire
IDEAYA Biosciences Completes Targeted Full Enrollment in Randomized Pivotal Phase 2/3 Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in First-line HLA*A2-Negative Metastatic Uveal Melanoma
IDEAYA Biosciences Completes Targeted Full Enrollment in Randomized Pivotal Phase 2/3 Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in First-​line HLA*A2-...
10.12.25 - PR Newswire
IDEAYA Biosciences Announces IND Submission for IDE574, a Potential First-In-Class KAT6/7 Dual Inhibitor for Breast and Lung Cancers
IDEAYA Biosciences Announces IND Submission for IDE574, a Potential First-​In-Class KAT6/7 Dual Inhibitor for Breast and Lung Cancers PR Newswire
01.12.25 - PR Newswire
IDEAYA Biosciences Announces IND Clearance for IDE034, a Potential First-in-Class Bispecific B7H3/PTK7 TOP1 ADC Targeting Multiple Solid Tumor Types
IDEAYA Biosciences Announces IND Clearance for IDE034, a Potential First-​in-Class Bispecific B7H3/PTK7 TOP1 ADC Targeting Multiple Solid Tumor Types PR Newswire
28.11.25 - PR Newswire
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) PR Newswire
24.11.25 - PR Newswire
IDEAYA Biosciences to Participate in Upcoming December 2025 Investor Relations Events
IDEAYA Biosciences to Participate in Upcoming December 2025 Investor Relations Events PR Newswire
04.11.25 - PR Newswire
IDEAYA Biosciences Reports Third Quarter 2025 Financial Results and Provides Business Update
IDEAYA Biosciences Reports Third Quarter 2025 Financial Results and Provides Business Update PR Newswire
31.10.25 - PR Newswire
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) PR Newswire
27.10.25 - PR Newswire
IDEAYA Biosciences to Participate in Upcoming November 2025 Investor Relations Events
IDEAYA Biosciences to Participate in Upcoming November 2025 Investor Relations Events PR Newswire
20.10.25 - PR Newswire
IDEAYA Biosciences Announces Positive Phase 2 Data for Darovasertib in the Neoadjuvant Setting of Primary Uveal Melanoma in a Proffered Paper Oral Presentation at ESMO 2025
IDEAYA Biosciences Announces Positive Phase 2 Data for Darovasertib in the Neoadjuvant Setting of Primary Uveal Melanoma in a Proffered Paper Oral Presentation at ESMO 2025 ...
20.10.25 - PR Newswire
IDEAYA Biosciences Reports Positive Median Overall Survival Data from Phase 2 Trial of the Darovasertib and Crizotinib Combination in First-line Metastatic Uveal Melanoma at the 2025 Society for Melanoma Research Congress
IDEAYA Biosciences Reports Positive Median Overall Survival Data from Phase 2 Trial of the Darovasertib and Crizotinib Combination in First-​line Metastatic Uveal Melanoma at the ...
15.10.25 - PR Newswire
Next-Generation Targeted Therapies Reshape Precision Oncology Landscape
Next-​Generation Targeted Therapies Reshape Precision Oncology Landscape PR Newswire
15.10.25 - PR Newswire
Next-Generation Targeted Therapies Reshape Precision Oncology Landscape
Next-​Generation Targeted Therapies Reshape Precision Oncology Landscape PR Newswire
26.09.25 - PR Newswire
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) PR Newswire
08.09.25 - PR Newswire
Breakthrough Therapy Designations Surge as $50B Cancer Drug Partnerships Reshape Market
Breakthrough Therapy Designations Surge as $50B Cancer Drug Partnerships Reshape Market PR Newswire
08.09.25 - PR Newswire
Breakthrough Therapy Designations Surge as $50B Cancer Drug Partnerships Reshape Market
Breakthrough Therapy Designations Surge as $50B Cancer Drug Partnerships Reshape Market PR Newswire

Newssuche

Videos

newspaper
18.02.26 -2,76%
Technical Trading: Chance mit 82 Prozent Treffern
Rohöl Long Typ: Turbo Open End WKN: VH65XQ Hebel:6 Laufzeit: OpenEnd Einstieg: Market ... Mehr »
Anzeige

Aktie im Fokus

Breaking News
DiagnosTear Technologies Inc
0,268 €
+5,51%
DiagnosTear Technologies Inc Chart
TeaRx™ erobert Großbritannien im Sturm?!
Mehr zur Aktie »